中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2008年
5期
740-741
,共2页
心力衰竭%充血性%C反应蛋白质%普伐他汀
心力衰竭%充血性%C反應蛋白質%普伐他汀
심력쇠갈%충혈성%C반응단백질%보벌타정
Heart failure%congestive%C-reactive protein%Pravastatin
目的 探讨普伐他汀对慢性心力衰竭(CHF)患者心功能及血清C反应蛋白(CRP)水平的影响.方法 90例CHF患者随机分为他汀组(45例)和对照组(45例).他汀组在常规治疗基础上加用普伐他汀40mg/d;对照组常规治疗.两组患者治疗前、治疗后3个月检测血清CRP及行超声心动图检查测定左心室射血分数(LVEF).结果 两组患者治疗3个月后与治疗前比较,TC、血清CRP水平均有不同程度降低,且他汀组血清CRP水平较对照组明显下降[(15.47±9.83)mg/L,(20.31±7.15)mg/L,P<0.05],LVEF较对照组明显上升[(45.70±7.01)%,(38.34±5.31)%,P<0.05];血清CRP水平与LVEF呈负相关(r=-0.495,P<0.05).结论 普伐他汀能改善CHF患者的预后;血清CRP水平可作为治疗CHF的一个灵敏观察指标.
目的 探討普伐他汀對慢性心力衰竭(CHF)患者心功能及血清C反應蛋白(CRP)水平的影響.方法 90例CHF患者隨機分為他汀組(45例)和對照組(45例).他汀組在常規治療基礎上加用普伐他汀40mg/d;對照組常規治療.兩組患者治療前、治療後3箇月檢測血清CRP及行超聲心動圖檢查測定左心室射血分數(LVEF).結果 兩組患者治療3箇月後與治療前比較,TC、血清CRP水平均有不同程度降低,且他汀組血清CRP水平較對照組明顯下降[(15.47±9.83)mg/L,(20.31±7.15)mg/L,P<0.05],LVEF較對照組明顯上升[(45.70±7.01)%,(38.34±5.31)%,P<0.05];血清CRP水平與LVEF呈負相關(r=-0.495,P<0.05).結論 普伐他汀能改善CHF患者的預後;血清CRP水平可作為治療CHF的一箇靈敏觀察指標.
목적 탐토보벌타정대만성심력쇠갈(CHF)환자심공능급혈청C반응단백(CRP)수평적영향.방법 90례CHF환자수궤분위타정조(45례)화대조조(45례).타정조재상규치료기출상가용보벌타정40mg/d;대조조상규치료.량조환자치료전、치료후3개월검측혈청CRP급행초성심동도검사측정좌심실사혈분수(LVEF).결과 량조환자치료3개월후여치료전비교,TC、혈청CRP수평균유불동정도강저,차타정조혈청CRP수평교대조조명현하강[(15.47±9.83)mg/L,(20.31±7.15)mg/L,P<0.05],LVEF교대조조명현상승[(45.70±7.01)%,(38.34±5.31)%,P<0.05];혈청CRP수평여LVEF정부상관(r=-0.495,P<0.05).결론 보벌타정능개선CHF환자적예후;혈청CRP수평가작위치료CHF적일개령민관찰지표.
Objective To study the effect of pravastatin on cardiac function and serum C-reactive protein (CRP) levels in patients with chronic heart failure (CHF). Methods 90 patients with CHF were randomly divided into pravastatin group (n=45) and control group (n=45). Pravastatin 40mg/d was administered in addition to the routine treatment for pravastatin group; the control group was received the routine treatment. All patients with CHF were examined serum CRP levels, LVEF at pretherapy and 3 months by ultrasonic cardiogram. Results At 3 months C-reactive protein levels were degraded in varying degree, and the serum CRP levels in pravastatin group was significantly lower than that in control group [(15.47±9.83)mg/L vs (20.31±7.15)mg/L](P<0.05), LVEF was significantly higher than that in control group[(45.70±7.01)% vs (38.34±5.31)%](P<0.05); the serum CRP levels was positively related to LVEF (r=-0.495,P<0.05). Conclusion Pravastatin may improve the prognosis in patients with CHF, and can be used as a sensitive index for pravastatin treatment of CHF.
